Category: 8. Health

Patients with atopic dermatitis (AD) who were treated with Dupixent (dupilumab) had a 58% higher three-year risk of developing psoriasis compared to those receiving other non-topical therapies, according to a recent study published in JAMA Dermatology.

Dupixent is a widely used biologic treatment for moderate to severe AD, a chronic skin condition caused by inflammation that shows up as red or discolored patches that are very itchy.

While Dupixent has been proven effective and generally safe, a number of reports suggest that it may increase the risk of developing psoriasis—a different inflammatory skin disease typically involving scaly plaques that often feels more like stinging or burning.

AD affects nearly 32 million people in the U.S., while psoriasis affects approximately 7.55 million U.S. adults aged 20 years and older.

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation, according to study authors.

However, newer research has shown that these diseases can overlap in patients and may even share common pathways.

Blocking IL-4 and IL-13—the immune signals targeted by Dupixent—may unintentionally shift the immune balance toward Th17 activity, which is associated with psoriasis.

Some people receiving Dupixent for conditions such as asthma and alopecia areata have also developed psoriasis-like rashes, suggesting that the reaction may not be limited to those with AD.

In addition, joint pain resembling psoriatic arthritis has been reported.

While case reports have hinted at this connection for years, large-scale studies have been limited.

Researchers of the study conducted this retrospective cohort study to determine whether patients with AD treated with Dupixent had a higher risk of developing psoriasis compared to those receiving other treatments.

Deidentified health records from the TriNetX Global Network—which includes data from over 150 million patients across 17 countries—were used to identify eligible adults.

Participants were included if they had at least two AD diagnoses 30 days apart and initiated treatment with either Dupixent or another systemic therapy.

Patients with a history of psoriasis or prior use of similar biologics were excluded.

The study tracked new psoriasis diagnoses for up to three years, beginning one month after treatment started.

Researchers matched 9,860 Dupixent users to 9,860 control patients based on demographic and clinical factors to reduce bias.

They used several statistical methods to compare the groups, including ways to track how many people developed psoriasis over time and how significant the risk was.

Researchers also tested the results in different patient groups to make sure results were reliable.

In addition, a separate group of asthma patients without AD was studied to confirm the findings.

Results showed a 58% higher risk of psoriasis in the dupilumab group, though the absolute risk remained low.

Strengths & Limitations

This large study had several strengths, including the use of robust electronic health record data and a matched cohort design that reduced selection bias and allowed for a more accurate comparison between patients.

Researchers adjusted for factors including age, sex, race, comorbidities and lab results.

Multiple sensitivity and subgroup analyses, along with a validation study in patients with asthma, strengthened the reliability of the findings.

However, the study also had limitations.

Because the study was observational, it could not prove that Dupixent causes psoriasis.

The EHR data also lacked details on disease severity, treatment response and medication dosage or duration.

Some cases may have been misclassified due to limited diagnostic information, although efforts were made to reduce this risk.

The authors suggest that Dupixent could act as a trigger, rather than the sole cause, of psoriasis in those with certain immune profiles.

They recommend further research to better understand whether Dupixent also increases the risk of psoriatic arthritis and to explore differences among patient subgroups that may influence who is more vulnerable to these skin reactions.

^{Photo: LivMedCell via FL Communications}

ISTANBUL, July 08, 2025 (GLOBE NEWSWIRE) — LivMedCell has officially launched a groundbreaking research collaboration with the University of Pennsylvania’s Perelman School of Medicine to advance CAR-T cell therapy and personalized oncology.

The agreement, signed in late May 2025, is being publicly announced today as part of LivMedCell’s strategic expansion beyond regenerative medicine.

This initiative marks a new chapter in LivMedCell’s commitment to next-generation cellular therapies and positions the center at the forefront of innovative immunotherapy research.

Located in Istanbul, LivMedCell is Turkey’s first and only hospital-based stem cell production center operating under Good Manufacturing Practices (GMP) standards. Since 2014, the center has treated thousands of patients from Europe, the Middle East, Central Asia, and beyond — offering personalized, Ministry of Health-approved cellular therapies for a wide range of chronic and degenerative conditions.

Science Meets Clinical Impact: A Global Reference in Regenerative Medicine

^{Photo: The expert team behind LivMedCell – Turkey’s pioneering center for stem cell therapies.}

Led by Prof. PhD. Erdal Karaöz — an internationally recognized expert in stem cell and regenerative medicine with over 300 scientific publications and multiple global awards — LivMedCell has established itself as a reference center in the field. In addition to directing LivMedCell, Prof. PhD. Karaöz also serves as a faculty member at Istinye University, where he continues his academic contributions through research, teaching, and innovation in cellular therapies.

LivMedCell provides personalized stem cell and exosome treatments for:

• Neurological conditions: stroke, autism, cerebral palsy, spinal cord injury
• Pulmonary diseases: COPD, IPF, post-COVID lung damage
• Cardiac issues: ischemic heart disease, diabetic foot
• Musculoskeletal injuries: cartilage damage, tendon tears, avascular necrosis
• Autoimmune disorders: multiple sclerosis, lupus, Crohn’s
• Aesthetic & dermatological applications: skin rejuvenation, hair loss, wound healing
• Endocrine and urological issues: type 1 diabetes, ovarian insufficiency, erectile dysfunction

^{Photo: LivMedCell}

Each therapy is manufactured under GMP conditions and administered with multidisciplinary clinical oversight — a unique model that ensures both safety and efficacy.

Redefining Longevity: A Scientific Approach to Youth and Vitality

In a world obsessed with appearance, LivMedCell’s Longevity Program goes beyond the surface. Backed by cellular science, this unique approach offers not just aesthetic results — but true cellular rejuvenation.

At the heart of the program is a simple yet powerful idea:

“Don’t just look young — be young.”

By using GMP-certified stem cells and exosomes, LivMedCell’s longevity treatments aim to renew the body from within, restore damaged tissue, regulate inflammation, and slow biological aging.

Looking Ahead: CAR-T Cell Therapy Collaboration with UPenn

^{Photo: The Liv Hospital and Penn Medicine teams celebrating the launch of their groundbreaking academic collaboration in Istanbul.}

Taking a bold step into next-generation cellular treatments, LivMedCell has initiated a research collaboration with the University of Pennsylvania (UPenn) — a global leader in CAR-T cell therapy. While regenerative medicine remains the core focus, this partnership marks a strategic expansion into immunotherapy and personalized oncology.

Media Contact:

FL PR and Communications

asset@flcommunications.co.uk

+905330202554

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f85c9b27-3c9a-4cef-aebe-87019f1bafb3

https://www.globenewswire.com/NewsRoom/AttachmentNg/c292da7f-e559-4d38-978b-907ca5fbd70f

https://www.globenewswire.com/NewsRoom/AttachmentNg/ff9963d9-0f25-4ec0-bcfb-bf41477da0e7

https://www.globenewswire.com/NewsRoom/AttachmentNg/f8e6dacf-093c-45b8-a532-dbda6762da13

Thank you. Listen to this article using the player above. ✖

Researchers at Mayo Clinic have developed an artificial intelligence (AI) system capable of analyzing patient-submitted photographs of postoperative wounds to identify surgical site infections (SSIs).

The study, published in Annals of Surgery, describes a multi-step pipeline trained on more than 20,000 images collected from over 6,000 patients treated across 9 Mayo Clinic hospitals.

The AI system is trained to perform three functions: it first determines whether a submitted image contains a surgical incision, then assesses the quality of the image and finally evaluates the incision for signs of infection. 

Supporting outpatient recovery with automated screening

With the increasing shift to outpatient surgeries and virtual follow-up care, clinicians are often required to assess postoperative recovery remotely. This approach can delay diagnosis if images are not reviewed promptly. 

“We were motivated by the increasing need for outpatient monitoring of surgical incisions in a timely manner,” said Cornelius Thiels, D.O., a hepatobiliary and pancreatic surgical oncologist at Mayo Clinic and co-senior author of the study. “This process, currently done by clinicians, is time-consuming and can delay care. Our AI model can help triage these images automatically, improving early detection and streamlining communication between patients and their care teams.”

The model’s operates using a two-stage model. First, it begins with incision detection. If an incision is confirmed, the wound features are then assessed to evaluate whether there are any signs of infection.

The model has achieved 94% accuracy in identifying incision presence and achieved an area under the curve (AUC) of 0.81 in detecting infections. Critically, the model continued to perform at consistently high levels across diverse patient demographics, mitigating concerns over potential bias.

“Our hope is that the AI models we developed — and the large dataset they were trained on — have the potential to fundamentally reshape how surgical follow-up is delivered,” said Hojjat Salehinejad, Ph.D., a senior associate consultant of health care delivery research within the Kern Center for the Science of Health Care Delivery and co-senior author. “Prospective studies are underway to evaluate how well this tool integrates into day-to-day surgical care.”

Future applications in clinical workflows

Although the tool currently serves as a proof of concept, the research team is exploring how it could be used in real-world surgical care workflows.

“For patients, this could mean faster reassurance or earlier identification of a problem,” said Hala Muaddi, M.D., Ph.D., a hepatopancreatobiliary fellow at Mayo Clinic and first author. “For clinicians, it offers a way to prioritize attention to cases that need it most, especially in rural or resource-limited settings.”

The team are hopefully that this technology could help support patients who are recovering from surgery at home. With further validation, they believe it could be used as a frontline screening tool to alert physicians to potentially concerning incisions.

Reference: Hala Muaddi, Choudhary A, Lee F, et al. Imaging Based Surgical Site Infection Detection Using Artificial Intelligence. Ann Surg. 2025. doi: 10.1097/sla.0000000000006826

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

This content includes text that has been generated with the assistance of AI. Technology Networks’ AI policy can be found here.